Read more

October 14, 2019
1 min read
Save

FDA grants fast track designation to T-Guard for acute graft-versus-host disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted fast track designation to T-Guard for treatment of patients who develop steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

T-Guard (Xenikos) consists of two toxin-conjugated monoclonal antibodies that target CD3 and CD7 on T cells and natural killer cells.

Preclinical and early clinical studies showed the agent can identify and eliminate mature T cells and natural killer cells with minimal treatment-related side effects, according to a Xenikos-issued press release.

A phase 1/phase 2 study evaluated T-Guard as second-line treatment of steroid-refractory acute GVHD among patients who underwent hematopoietic stem cell transplantation. Results showed 1 week of T-Guard treatment doubled the 6-month OS and induced a strong clinical response, according to the release.

Xenikos is preparing to begin a pivotal phase 3 trial of T-Guard for steroid-refractory acute GVHD after allogeneic stem cell transplant.

“We are delighted that the FDA has given fast track designation to T-Guard, as this will support our goal of getting T-Guard to patients as quickly as possible,” Ypke van Oosterhout, PhD, CEO of Xenikos, said in the press release. “We’re also looking forward to starting our phase 3 pivotal trial in the U.S. Effective new therapies for treating steroid-refractory acute GVHD are urgently needed, and we believe that T-Guard — which can rapidly and safely reset the patient’s immune system — has the potential to provide an important new treatment option to patients with this devastating, potentially fatal condition.”